

8IP Australian Equity Impact Fund

Invest to accelerate progress

Our Impact Focus Areas



Renewable Energy
4.3%



Energy Storage & efficiency
3.1%



Wellbeing: Pharmaceuticals
3.3%



Care and Support
10.8%



Affordable housing
3.1%



Land and Resource Management
7.6%



Wellbeing: Medical devices
10.9%



Wellbeing: Health Care services
11.0%



Education
14.9%



Lifestyle and Healthy Living
11.8%

Portfolio Update

During the quarter, we initiated new positions in *Envirosuite*, *G8 Education*, *Mayfield Childcare*, *Paradigm Biopharmaceuticals*, and *Resmed*.

Envirosuite has developed a comprehensive real-time monitoring, investigative and predictive environmental management software system. It is commonly used to ensure environmental compliance with a particular focus on air, noise, and water pollution. However, it can be used to reduce pollution given the predictive ability of the software and to reduce the negative impacts of unforeseen adverse events through real-time monitoring. The company has won contracts globally, including with New Thames Water in the UK, Veolia in France, the LA and San Francisco Air Districts in the US, and SA Water in Australia.

We added *G8 Education* and *Mayfield* in the childcare sector to our existing position in Think Childcare. The sector is suffering from oversupply in the short-term but there will be a need for additional investment in the long-term and the current share price weakness provides the opportunity to increase exposure.

Paradigm is focused on repurposing an existing drug, pentosane polysulphate sodium (PPS), for various new treatments, including for inflammatory joint disease. The benefit of repurposing an existing drug is that the development program is usually faster and less costly than for completely new drugs. *Paradigm* has announced encouraging early results, achieving significant reductions in pain for patients with osteoarthritis.

Resmed is a major global manufacturer of devices for the treatment of sleep disorders which has been gaining market share as a result of their product innovation.

Key Facts

Inception	31 January 2017
Domicile & Status	Registered Managed Investment Scheme domiciled in Australia
Holdings	28 stocks
Liquidity	Daily
Base Currency	Australian dollars
Distributions	Paid annually, shortly after 30 June; reinvested unless otherwise instructed
Minimum Investment	\$10,000

Fund Snapshot

- The Fund aims to deliver outperformance above the S&P/ASX All Ordinaries Accumulation Index.
- Diversified portfolio of Australian equities across a range of impact focus areas.
- The Fund aims to demonstrate a financial return and a measurable and positive impact on society or the environment.

Why Impact Investing?

Directing capital to solve problems is more effective if the for-profit business sector is actively engaged. Your capital is invested in companies that **generate positive social and environmental impacts along with financial returns.**

The industries in which these companies operate tend to have structural growth tailwinds which, when combined with active stock selection, provides the opportunity to generate **superior investment returns.**

Why Eight Investment Partners (“8IP”)?

As a specialist equity investor with a focus on small company investing, 8IP has the investment resources and network to identify companies that combine positive impact with attractive investment potential.

8IP manages in excess of A\$200m focused on ASX listed small companies on behalf of institutions, high net worth individuals and a listed investment company. The portfolios are managed by Kerry Series and Stephen Walsh, both experienced equity investors.

Performance

	3 months	6 months	1 year	Inception (%pa)
Fund (gross-of-fees)	-0.43%	-0.18%	+15.99%	+15.10%
Index	+1.86%	+10.05%	+14.67%	+11.65%
Active Return (gross-of-fees)	-2.29%	-10.23%	+1.32%	+3.45%


Source: 8IP and S&P.

All returns are shown to two decimal places. Current month performance is a manager estimate. Returns for periods of more than one year are annualised. Total returns include realised and unrealised gains and losses plus income and are time-weighted rates of return that adjust for external cash flows. Valuations are computed and performance reported in Australian dollars. Gross-of-fees performance returns are presented before management and performance fees but after all trading expenses. Past performance is not an indicator of future performance.

Top 5 Holdings

Probiotec Limited	6.63%
Redhill Education Limited	6.28%
Genex Power Limited	4.28%
Envirosuite Limited	3.91%
Cleanaway Waste Management Limited	3.61%

Sector Allocation



Source: 8IP and Bloomberg. Please note that 8IP may reallocate stocks' sector classifications where in 8IP's view it is appropriate to do so.

Fees

Investment Management Fee	1.03% p.a.
Other Fees and Expenses	Up to 0.36% p.a.
Total Management Costs	1.39% p.a.
Performance Fee	20.5% over benchmark
Benchmark	S&P/ASX All Ordinaries Accumulation Index

Fees and expenses are inclusive of net GST.

Fund Identifiers

APIR	ETL6826AU
------	-----------

IMPORTANT INFORMATION

This report was prepared by Eight Investment Partners Pty Limited (ABN 22 139 616 783, AFSL 342 305) as promoter of the Fund. The Fund was launched as an unregistered managed investment scheme on 31 January 2017 and registered with ASIC as a retail scheme on 6 March 2018. Equity Trustees Limited (Equity Trustees) (ABN 46 004 031 298, AFSL 240 975) is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX:EQT). Equity Trustees was appointed Trustee of the Fund on 31 January 2017 and responsible entity on 6 March 2018.

This document has been prepared for the purpose of providing general information only, without taking account of your particular investment objectives, financial circumstances or needs. It is not intended to take the place of professional advice and we do not express any view about the accuracy or completeness of information that is not prepared by us and no liability is accepted for any errors it may contain. You should consider the Product Disclosure Statement (“PDS”) in deciding whether to acquire, or continue to hold, the product. A PDS and application form is available at www.8ip.com.au.

Neither Equity Trustees nor 8IP guarantees the performance of the Fund or the repayment of any investor's capital. To the extent permitted by law, neither Equity Trustees nor 8IP, including their employees, consultants, advisers, officers or authorised representatives, are liable for any loss or damage arising as a result of reliance placed on the contents of this report. Past performance is not indicative of future performance.